Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Tysabri, the MS Drug Haunted by Deadly Side Effect, Doesn’t Look So Deadly Anymore
|
Luke Timmerman |
11/19/09 |
Boston
|
|
Calistoga Cancer Drug Shows “Encouraging” Preliminary Results in Small Study
|
Luke Timmerman |
10/19/09 |
Seattle
|
|
Seattle Genetics Shares Drop on Halted Lymphoma Trial
|
Luke Timmerman |
10/05/09 |
Seattle
|
|
Seattle Genetics, Bucking the Trend, Recruits Hodgkin’s Patients at Warp Speed
|
Luke Timmerman |
08/12/09 |
Seattle
|
|
Biogen Idec, Trying to Go Beyond Rituxan, Assembles Cancer Drug Pipeline
|
Luke Timmerman |
07/16/09 |
Boston
|
|
Agios Lands Genentech Cancer Drug Leader as New CEO
|
Luke Timmerman |
05/27/09 |
Boston
|
|
How to Raise $50M in a Recession: Highlights from the Xconomy Life Sciences Forum
|
Luke Timmerman |
05/01/09 |
Boston
|
|
Biogen Idec, Extending Life of its Top-Selling Drug, Eyes Longer-Lasting Shot for MS
|
Luke Timmerman |
03/27/09 |
Boston
|
|
Trubion Starts Lupus Trial
|
Luke Timmerman |
03/25/09 |
Seattle
|
|
Biogen Idec, Genentech’s Rituxan Fails in Pivotal Study of Lupus of Kidneys
|
Luke Timmerman |
03/11/09 |
Boston
|
|
Trubion Cuts One-Fourth of Workforce
|
Luke Timmerman |
02/25/09 |
Seattle
|
|
Pfizer’s Bid For Wyeth Sends Ripples Through Trubion Pharmaceuticals, Seattle Biotechs
|
Luke Timmerman |
01/27/09 |
Seattle
|
|
Biogen Idec VC Group Sees Opportunity in Tough Market, Has $100M New Allocation to Invest in Biotech Firms
|
Ryan McBride |
12/12/08 |
San Diego
|
|
Blood News: A Quick Rundown of Headlines From the American Society of Hematology
|
Luke Timmerman |
12/09/08 |
National
|
|
Seattle Genetics “Empowered Antibody” Shines at Blood Disease Meeting
|
Luke Timmerman |
12/06/08 |
Seattle
|
|
Biogen Pays $31.5M to Genentech to Co-Develop Anti-CD20 Drug
|
Luke Timmerman |
11/03/08 |
Boston
|
|
Trubion Shares Leap, Drop, Leap Again After Encouraging Clinical Trial News
|
Luke Timmerman |
10/27/08 |
Seattle
|
|
Calistoga Builds Cancer Drug Strategy, Hires First CEO, Carol Gallagher
|
Luke Timmerman |
10/08/08 |
Seattle
|
|
Trubion Wins Patent Dispute With Genentech, Biogen Idec
|
Luke Timmerman |
09/11/08 |
Seattle
|
|
Seattle Genetics’ Medical Point Man, Tom Reynolds, Aims to Capitalize on Hodgkin’s Drug
|
Luke Timmerman |
09/08/08 |
Seattle
|
|
Discovery: The Soul of Biotech, the Place For True Believers, and a Retro Way to Bring it Back
|
Johnny Stine |
09/08/08 |
Seattle
|
|
ZymoGenetics Hands Over Atacicept Rights to Partner, Merck KGaA
|
Luke Timmerman |
09/03/08 |
Seattle
|
|
Trubion Pushing Forward Arthritis Trials, Working to Re-Ignite the Spark for Investors
|
Luke Timmerman |
08/26/08 |
Seattle
|
|
The Future of Biotech Is in Rabbits, Says Entrepreneur Johnny Stine
|
Luke Timmerman |
07/30/08 |
Seattle
|
|
Biogen Idec Isn’t Sweating Possible Sale of Genentech to Roche
|
Luke Timmerman |
07/22/08 |
Boston
|
|
Genzyme Reaching For a Slice From Biogen’s Breadbasket, Multiple Sclerosis Drugs
|
Luke Timmerman |
07/17/08 |
Boston
|
|
Page 1 of
1 |
|
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
